One such case resulting in a death was reported in a 2006 article from Japan and the authors suggest a " an inter-racial difference " for the interstitial pneumonitis.
12.
Nilutamide shows unique and unfavorable tolerability and toxicity profiles, most importantly a high incidence of interstitial pneumonitis ( which can progress to pulmonary fibrosis, a potentially fatal condition ), and this has limited its clinical use.
13.
From a safety standpoint, bicalutamide is clinically preferred not only over nilutamide ( due primarily to its risk of interstitial pneumonitis ) but also flutamide ( due to its high risk of hepatotoxicity ) in choice of NSAA.
14.
While HRCT may be able to identify pulmonary fibrosis, it may not always be able to further categorize the fibrosis to a specific pathological type ( e . g ., non-specific intersitial pneumonitis or desquamative interstitial pneumonitis ).
15.
Acute interstitial pneumonitis is often categorized as both an interstitial lung disease and a form of acute respiratory distress syndrome ( ARDS ) but it is distinguished from the " chronic " forms of interstitial pneumonia such as idiopathic pulmonary fibrosis.
16.
A study has shown that acute exposure ( 4 8 hours ) to calculated elemental mercury levels of 1.1 to 44 mg / m 3 resulted in chest pain, dyspnea, cough, hemoptysis, impairment of pulmonary function, and evidence of interstitial pneumonitis.
17.
Severe adverse events identified during the EMILIA trial included hepatotoxicity ( liver damage ), including rare cases of liver failure, hepatic encephalopathy, and nodular regenerative hyperplasia; heart damage ( dysfunction of the left ventricle ); interstitial lung disease, including acute interstitial pneumonitis; thrombocytopenia; and peripheral neuropathy.
18.
In fact, the incidence of diarrhea did not differ between the bicalutamide and placebo groups ( 6.3 % vs . 6.4 %, respectively ) in the trial, In addition, bicalutamide ( and flutamide ) is not associated with above, bicalutamide appears to have the lowest relative risks of hepatotoxicity and interstitial pneumonitis, with respective incidences far below those of flutamide and nilutamide.
